Effectiveness of a pharmacist-led protocol to manage cystitis in women, in France: the PharmaCyst' open-label, multicenter, randomized, controlled, cluster study.

Res Social Adm PharmJul 1, 2026 (epub)
Clinical ResearchUrology

Arthur Piraux, Jean-François Hamel, Elsa Parot-Schinkel et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter, randomized controlled trial evaluated the effectiveness of a pharmacist-led protocol for managing uncomplicated cystitis in women aged 18 to 65 in France. The study found that the intervention group experienced a greater reduction in the Acute Cystitis Symptom Score (ACSS) at day 3, with a score change of -8.21 compared to -5.84 in the control group (p = 0.035).

Key findings

  • The intervention group had a greater ACSS score reduction at day 3: -8.21 vs -5.84.
  • Patient satisfaction with pharmacist care was high, with a mean score of 9.66 out of 10.
  • No significant differences in adverse events or complications were noted between the two groups.

Why it matters

The findings suggest that pharmacist-led management of uncomplicated cystitis can effectively reduce symptoms and enhance patient satisfaction, potentially improving access to care in settings where physician availability is limited.

Source

PubMed · PMID 42386490

Published in Res Social Adm Pharm. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.